Significance of MMP-2 Expression in Prostate Cancer: An Immunohistochemical Study

Cancer Research

Volumn 63, Issue 23, 2003, Pages 8511-8515

  Trudel, Dominique ^a   Fradet, Yves ^a   Meyer, François ^a   Harel, François ^a   Têtu, Bernard ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; DISEASE COURSE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NORTH AMERICA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STROMA CELL;

ADULT; AGED; COHORT STUDIES; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0345734264     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Neal, D. E., Leung, H. Y., Powell, P. H., Hamdy, F. C., and Donovan, J. L. Unanswered questions in screening for prostate cancer. Eur. J. Cancer, 36: 1316-1321, 2000.
2. Hsing, A. W., Tsao, L., and Devesa, S. S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer, 85: 60-67, 2000.
3. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., and Walsh, P. C. Natural history of progression after PSA elevation following radical prostatectomy. J. Am. Med. Assoc., 281: 1591-1597, 1999.
4. Nelson, A. R., Fingleton, B., Rothenberg, M. L., and Matrisian, L. M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol., 18: 1135-1149, 2000.
5. Chambers, A. F., and Matrisian, L. M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst., 89: 1260-1270, 1997.
6. DeClerck, Y. A., Imren, S., Montgomery, A. M., Mueller, B. M., Reisfeld, R. A., and Laug, W. E. Proteases and protease inhibitors in tumor progression. Adv. Exp. Med. Biol., 425: 89-97, 1997.
7. Noel, A., Albert, V., Bajou, K., Bisson, C., Devy, L., Frankenne, F., Maquoi, E., Masson, V., Sounni, N. E., and Foidart, J. M. New functions of stromal proteases and their inhibitors in tumor progression. Surg. Oncol. Clin. North Am., 10: 417-432, 2001.
8. Brew, K., Dinakarpandian, D., and Nagase, H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta, 1477: 267-283, 2000.
9. Hidalgo, M., and Eckhardt, S. G. Matrix metalloproteinase inhibitors: how can we optimize their development? Ann. Oncol., 12: 285-287, 2001.
10. Vihinen, P., and Kahari, V. M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer, 99: 157-166, 2002.
11. Afzal, S., Laiani, E. N., Poulsom, R., Stubbs, A., Rowlinson, G., Sato, H., Seiki, M., and Stamp, G. W. MTI-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum. Pathol., 29: 155-165, 1998.
12. Davidson, B., Goldberg, I., Gotlieb, W. H., Kopolovic, J., Ben Baruch, G., Nesland, J. M., Berner, A., Bryne, M., and Reich, R. High levels of MMP-2, MMP-9, MTI-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin. Exp. Metastasis, 17: 799-808, 1999.
13. Sakata, K., Shigemasa, K., Nagai, N., and Ohama, K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MTI-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int. J. Oncol., 17: 673-681, 2000.
14. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A., and Balkwill, F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
15. Gohji, K., Fujimoto, N., Fujii, A., Komiyama, T., Okawa, J., and Nakajima, M. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. Cancer Res., 56: 3196-3198, 1996.
16. Kanayama, H., Yokota, K., Kurokawa, Y., Murakami, Y., Nishitani, M., and Kagawa, S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer (Phila.), 82: 1359-1366, 1998.
17. Dumas, V., Kanitakis, J., Charvat. S., Euvrard, S., Faure, M., and Claudy, A. Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas. Anticancer Res., 19: 2929-2938, 1999.
18. Ikebe, T., Shinohara, M., Takeuchi, H., Beppu, M., Kurahara, S., Nakamura, S., and Shirasuna, K. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin. Exp. Metastasis, 17: 315-323, 1999.
19. Mori, M., Mimori, K., Shiraishi, T., Fujie, T., Baba, K., Kusumoto, H., Haraguchi, M., Ueo, H., and Akiyoshi, T. Analysis of MTI-MMP and MMP2 expression in human gastric cancers. Int. J. Cancer, 74: 316-321, 1997.
20. Pacheco, M. M., Mourao, M., Mantovani, E. B., Nishimoto, I. N., and Brentani, M. M. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-palhological correlations. Clin. Exp. Metaslasis, 16: 577-585, 1998.
21. Talvensaari-Maltila, A., Paakko, P., Blanco-Sequeiros, G., and Turpeenniemi-Hujanen, T. Matrix melalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy. Breast Cancer Res. Treat., 65: 55-61, 2001.
22. Nuovo, G. J., MacConnell, P. B., Simsir, A., Valea, F., and French, D. L. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res., 55: 267-275, 1995.
23. Fridman, R., Toth, M., Pena, D., and Mobashery, S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res., 55: 2548-2555, 1995.
24. Itoh, T., Tanioka, M., Matsuda, H., Nishimoto, H., Yoshioka, T., Suzuki, R., and Uehira, M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastasis, 17: 177-181, 1999.
25. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol., 2: 737-744, 2000.
26. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc. Natl. Acad. Sci. USA, 98: 119-124, 2001.
27. Boag, A. H., and Young, I. D. Increased expression of the 72-kd type IV collagenase in prostatic adenocarcinoma. Demonstration by immunohistochemistry and in situ hybridization. Am. J. Pathol., 144: 585-591, 1994.
28. Still, K., Robson, C. N., Autzen, P., Robinson, M. C., and Hamdy, F. C. Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. Prostate, 42: 18-25, 2000.
29. Pajouh, M. S., Nagle, R. B., Breathnach, R., Finch, J. S., Brawer, M. K., and Bowden, G. T. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res. Clin. Oncol., 117: 144-150, 1991.
30. Stearns, M., and Stearns, M. E. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol. Res., 8: 69-75, 1996.
31. Stearns, M. E., and Stearns, M. Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer. Oncol. Res., 8: 63-67, 1996.
32. r 72,000) expression in human prostate: benign and malignant tissue. Cancer Res., 53: 878-883, 1993.
33. Wood, M., Fudge, K., Mohler, J. L., Frost, A. R., Garcia, F., Wang, M., and Stearns, M. E. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis, 15: 246-258, 1997.
34. Kuniyasu, H., Troncoso, P., Johnston, D., Bucana, C. D., Tahara, E., Fidler, I. J., and Pettaway, C. A. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin. Cancer Res., 6: 2295-2308, 2000.
35. Ross, J. S., Kaur, P., Sheehan, C. E., Fisher, H. A., Kaufman, R. A., Jr., and Kallakury, B. V. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod. Pathol., 16: 198-205, 2003.
36. Vaillancourt, L., Têtu, B., Fradet, Y., Dupont, A., Gomez, J., Cusan, L., Suburu, E. R., Diamond, P., Candas, B., and Labrie, F. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. A randomized study. Am. J. Surg. Pathol., 20: 86-93, 1996.
37. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
38. Austin JC, and Williams RD. Staging failures of initial therapy. In: M. I. Resnick and I. M. Thompson (eds.), Advanced Therapy of Prostate Disease, pp. 340-352. London: B. C. Decker, 2000.
39. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I., and Walsh, P. C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol. Clin. North Am., 20: 713-725, 1993.
40. Montironi, R., Fabris, G., Lucarini, G., and Biagini, G. Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Pathol. Res. Pract., 191: 1140-1146, 1995.
41. Sternlicht, M. D., and Werb, Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol., 17: 463-516, 2001.
42. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 9: 541-573, 1993.
43. Nagase, H. Cell surface activation of progelatinase A (proMMP-2) and cell migration. Cell Res., 8: 179-186, 1998.
44. Coussens, L. M., Fingleton, B., and Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash. DC), 295: 2387-2392, 2002.
45. Zucker, S., Cao, J., and Chen, W. T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene, 19: 6642-6650, 2000.